29. May 2026
Zedira Presents First Transglutaminase Award at FEBS Advanced Course 2026 in Padova
Zedira participated in the FEBS Advanced Course “Transglutaminases in Biological Processes”, held from May 25 to 29, 2026 in Padova, Italy.
As part of the scientific program, Zedira introduced the Zedira Transglutaminase Award for ‘Best Talk’, recognizing outstanding contributions to transglutaminase research. The award was presented by Dr. Ralf Pasternack, CEO of Zedira GmbH.
The first recipient of the award is Dr. Mara-Luciana Floare (Sheffield Institute of Translational Neuroscience (SITraN), The University of Sheffield), who was honoured for her presentation:
“Cerebellar Transcriptomic Signatures Implicate Protein Turnover and Mitochondrial Dysfunction in Gluten Ataxia”
Scientific Background of the Award-Winning Work:
Gluten ataxia represents the most common neurological manifestation of gluten sensitivity and is associated with autoimmune responses against transglutaminase 6 (TG6).
In her study, Dr. Floare investigated the transcriptomic profile of cerebellar tissue from patients with gluten ataxia compared to both healthy controls and patients with genetic forms of ataxia. Using microarray-based analysis, her team identified more than 2,000 significantly differentially expressed genes in gluten ataxia.
The results highlighted a marked upregulation of pathways involved in:
• protein degradation
• mitochondrial function and ATP production
At the same time, specific ribosomal RNA components were found to be downregulated.
These findings point towards a characteristic cellular stress response in affected neurons, likely driven by factors such as protein misfolding and oxidative stress. Notably, the observed molecular patterns showed strong similarities to those seen in genetic ataxias, suggesting shared mechanisms underlying cerebellar neurodegeneration.
The Zedira Transglutaminase Award, endowed with 500 € in Zedira products, is designed to support and encourage innovative young researchers in the field.
With this initiative, Zedira underlines its commitment to advancing scientific excellence and fostering cutting-edge research in transglutaminase biology.
As part of the scientific program, Zedira introduced the Zedira Transglutaminase Award for ‘Best Talk’, recognizing outstanding contributions to transglutaminase research. The award was presented by Dr. Ralf Pasternack, CEO of Zedira GmbH.
The first recipient of the award is Dr. Mara-Luciana Floare (Sheffield Institute of Translational Neuroscience (SITraN), The University of Sheffield), who was honoured for her presentation:
“Cerebellar Transcriptomic Signatures Implicate Protein Turnover and Mitochondrial Dysfunction in Gluten Ataxia”
Scientific Background of the Award-Winning Work:
Gluten ataxia represents the most common neurological manifestation of gluten sensitivity and is associated with autoimmune responses against transglutaminase 6 (TG6).
In her study, Dr. Floare investigated the transcriptomic profile of cerebellar tissue from patients with gluten ataxia compared to both healthy controls and patients with genetic forms of ataxia. Using microarray-based analysis, her team identified more than 2,000 significantly differentially expressed genes in gluten ataxia.
The results highlighted a marked upregulation of pathways involved in:
• protein degradation
• mitochondrial function and ATP production
At the same time, specific ribosomal RNA components were found to be downregulated.
These findings point towards a characteristic cellular stress response in affected neurons, likely driven by factors such as protein misfolding and oxidative stress. Notably, the observed molecular patterns showed strong similarities to those seen in genetic ataxias, suggesting shared mechanisms underlying cerebellar neurodegeneration.
The Zedira Transglutaminase Award, endowed with 500 € in Zedira products, is designed to support and encourage innovative young researchers in the field.
With this initiative, Zedira underlines its commitment to advancing scientific excellence and fostering cutting-edge research in transglutaminase biology.
Update zur Zöliakie-Studie: Teilnehmer ab Juni 2026 gesucht! 
Professor Kiyotaka Hitomi vistits Zedira 
Successful ISO9001:2015 recertification 
Besuch des Bundesministers für Wirtschaft und Klimaschutz Dr. Robert Habeck bei der Zedira 
Discover Our New Catalogue Edition and Dive into the World of Transglutaminases! 
Successful ISO9001:2015 recertification 
Dr. Falk Pharma and Zedira announce successful completion of the phase 2a proof-of-concept study of ZED1227 for the treatment of Celiac Disease 
Dr. Falk Pharma und Zedira verkünden den erfolgreichen Abschluss der Phase 2a-Studie mit ZED1227 zur Behandlung von Zöliakie 
Reversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis 
Enzymatic Crosslinking of Gelatin: How Andracon® MTG Enables Tunable, Physiologically Compatible Hydrogels 
Transcriptomic analysis of the efficacy of TG2-inhibitor trials and human intestinal organoids modelling Celiac disease pathogenesis 
Transglutaminase antibodies and neurological manifestations of gluten sensitivity 
Design of Oral FXIIIa Blockers as Safer Anticoagulants Mission Impossible? 
Microbial transglutaminase (MTG) enables efficient and site-specific conjugation to native antibodies without the need of antibody engineering 
Tridegin as FXIIIa inhibitor 
Microbial transglutaminase: from discovery to market 
Tissue transglutaminase inhibitors 
Tissue transglutaminase in Alzheimers Disease 
Factor XIIIa: novel target for anticoagulation? 
Microbial transglutaminase for site-specific protein conjugation